Skip to main content
SpringerLink
Log in

Focal or Subtotal Therapy for Early Stage Prostate Cancer

  • Genitourinary Cancer
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Focal treatment for prostate cancer is highly intriguing, but poorly supported by the published literature. Further studies, preferably randomized controlled trials, are needed before this can be considered standard therapy. Focal treatment should be reserved for patients with focal disease. Even “clinically insignificant” synchronous tumors are malignant, and carry risk of progression if not treated with the index lesion. Whether these are likely to progress in this setting compared to those managed with active surveillance is unknown. The limited data regarding subtotal or focal cryotherapy suggest that patients properly evaluated for presence of satellite tumors have a low risk of having large unknown satellite tumors. The author requires office-based saturation biopsy prior to considering focal cryotherapy. Observation of prostatic intraepithelial neoplasia (PIN), atypical findings (ASAP), or cancer on the contralateral biopsy cores excludes the patient from consideration of subtotal therapy. MRI offers a potential additional ability to detect occult contralateral tumors. Younger men paradoxically seem to have greater interest in focal therapy while having a higher risk of future malignancy in the untreated areas based on the years of potential risk. However, no age cutoff is established. Without published data to support its use, lumpectomy or freezing only the focus where cancer is believed to exist, will remain limited. Hemispheric or subtotal treatment decreases the amount of untreated tissue. As a result, the local failure rate would be predicted to be lower but is unknown. When performing subtotal treatment, the author freezes almost the entire gland, sparing only the aspect adjacent to the contralateral neurovascular bundle, and has found this practice to be of highly limited utility based on the issues described. Biopsy should be performed following any treatment that fails to target the entire gland. A positive biopsy should be dealt with based on clinical factors as if the patient had not been treated, and a positive biopsy should not preclude active surveillance if deemed appropriate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: ● Of importance ●● Of major importance

  1. Hall GS, Kramer CE, Epstein JI: Evaluation of radical prostatectomy specimens. A comparative analysis of sampling methods. Am J Surg Pathol 1992 16(4):315–324

    Article  CAS  PubMed  Google Scholar 

This large study identifies the likelihood of having multifocal tumors, and suggests that features of the index tumor primarily determine biological behavior.

  1. Villers A, McNeal JE, Freiha FS, et al.: Multiple cancers in the prostate. Morphologic features of clinically recognized vs. incidental tumors. Cancer 1992, 70(9): 2312–2318

    Article  Google Scholar 

  2. Rukstalis DB , Goldknoph JL, Crowley EM, et al.: Prostate cryoablation: a scientific rationale for future modifications. Urology 2002, 60(2 Suppl 1):19–25

    Article  PubMed  Google Scholar 

  3. Byar DP, Mostofi FK, Veterans Administrative Cooperative Urologic Research Groups: Carcinoma of the prostate; prognostic evaluation of certain pathologic features in 208 radical prostatectomies. Cancer 1972, 30:5–13

    Google Scholar 

  4. Mouraviev V, Mayes JM, Madden JF, Sun L, Polascik TJ: Analysis of laterality and percentage of tumor involvement in 1386 prostatectomized specimens for selection of unilateral focal cryotherapy. Technol Cancer Res Treat. 2007 6(2):91–95

    PubMed  Google Scholar 

  5. Djavan B, Zlotta AR, Remzi M, et al.: Total and transition zone prostate volume and age: how do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection? Urology 1999, 54(5):846–852

    Article  CAS  PubMed  Google Scholar 

  6. Epstein JI, Walsh PC, Akingba G, et al.: The significance of prior benign needle biopsies in men subsequently diagnosed with prostate cancer. J Urol 1999, 162(5):1649–1652

    Article  CAS  PubMed  Google Scholar 

  7. Applewhite JC, Matagla BR, McCullough D: Results of the 5 region prostate biopsy method: the repeat biopsy population. J Urol 2002, 168:500–503

    Article  PubMed  Google Scholar 

This study was the first to demonstrate that the false negative rate for sextant biopsy is probably around 50%.

  1. Keetch DW, Catalona WJ, Smith DS: Serial prostate biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 1994, 151: 1571

    CAS  PubMed  Google Scholar 

  2. Epstein JI, Walsh PC, Carter HB: Importance of posterolateral needle biopsies in the detection of prostate cancer. Urology 2001, 57:1112

    Article  CAS  PubMed  Google Scholar 

  3. Walz J, Graefen M, Chun FK, Erbersdobler A, Haese A, Steuber T, Schlomm T, Huland H, Karakiewicz PI: High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. Eur Urol 2006 Mar 29

  4. Patel MI, DeConcini DT, Lopez-Corona E, Ohori M, Wheeler T, Scardino PT: An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol 2004 171(4):1520–1524

    Article  PubMed  Google Scholar 

  5. Bott SR, Henderson A, Halls JE, Montgomery BS, Laing R, Langley SE: Extensive transperineal template biopsies of prostate: modified technique and results. Urology 2006 68(5):1037–1041

    Article  PubMed  Google Scholar 

  6. Satoh T, Matsumoto K, Fujita T, Tabata K, Okusa H, Tsuboi T, Arakawa T, Irie A, Egawa S, Baba S: Cancer core distribution in patients diagnosed by extended transperineal prostate biopsy. Urology 2005 66(1):114–118

    Article  PubMed  Google Scholar 

  7. Moran BJ, Braccioforte MH, Conterato DJ: Re-biopsy of the prostate using a stereotactic transperineal technique. J Urol 2006 176(4 Pt 1):1376–1381

    Article  PubMed  Google Scholar 

  8. Kirkham AP, Emberton M, Allen C: How good is MRI at detecting and characterising cancer within the prostate? Eur Urol 2006 50(6):1163–1174

    Article  PubMed  Google Scholar 

  9. Ikonen S, Karkkainen P, Kivisaari L, Salo JO, Taari K, Vehmas T, Tervahartiala P, Rannikko S: Magnetic resonance imaging of clinically localized prostatic cancer.J Urol 1998 159(3):915–919

    Article  CAS  PubMed  Google Scholar 

Early study demonstrating the ability of MRI to detect prostate tumors, although tumors less than 5 mm are unlikely to be detected.

  1. Jager GJ, Ruijter ET, van de Kaa CA, de la Rosette JJ, Oosterhof GO, Thornbury JR, Ruijs SH, Barentsz JO: Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results.Radiology 1997 203(3):645–652

    CAS  PubMed  Google Scholar 

Study demonstrating that contrast enhancement improves MRI tumor detection.

  1. Schlemmer HP, Merkle J, Grobholz R, Jaeger T, Michel MS, Werner A, Rabe J, van Kaick G: Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? Eur Radiol 2004 14(2):309–317

    Article  PubMed  Google Scholar 

  2. Sodee DB, Sodee AE, Bakale G: Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med 2007 37(1):17–28

    Article  PubMed  Google Scholar 

  3. Donnelly BJ, Saliken JC, Ernst DS, Ali-Ridha N, Brasher PMA, Robinson JW, Rewcastle JC: A prospective trial of cryosurgical ablation of the prostate: five-year results. Urology 2002 60(4):645–649

    Article  CAS  PubMed  Google Scholar 

  4. Bahn DK, Lee F, Badalament R, Kumar A, Greski J, Chernick M: Target cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology 2002, 60 (Supp 2A): 3–11

    Article  PubMed  Google Scholar 

The first large study to demonstrate durable results using cryoablation to treat prostate cancer.

  1. Ellis DS: Cryosurgery as primary treatment for localized prostate cancer. A community hospital experience. Urology 2002, 60 (Supp 2A): 34–39

    Article  PubMed  Google Scholar 

  2. Ellis DS, Manny TB Jr, Rewcastle JC: Cryoablation as primary treatment for localized prostate cancer followed by penile rehabilitation. Urology. 2007 69(2):306–310

    Article  PubMed  Google Scholar 

The first study to challenge the concept that whole gland cryotherapy leads to universal erectile dysfunction. Penile rehabilitation appeared to improve the potency rate substantially.

  1. Onik G, Narayan P, Vaughan D, et al.: Focal “nerve-sparing” cryosurgery for treatment of primary prostate cancer: a new approach to preserving potency. Urology 2002, 60(1):109–114

    Article  PubMed  Google Scholar 

The first report of focal therapy using cryotherapy.

  1. Onik G: The male lumpectomy: rationale for a cancer targeted approach for prostate cryoablation. A review. Technol Cancer Res Treat. 2004 3(4):365–370

    PubMed  Google Scholar 

  2. Catalona WA, Carvalhal GF, Mager DE, Smith DS: Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol 1999, 162:433–438

    Article  CAS  PubMed  Google Scholar 

Large single-surgeon series with results that could be considered “setting the bar” for outcomes following prostate cancer treatments.

  1. Mulhall JP, Graydon RJ: The hemodynamics of erectile dysfunction following nerve-sparing radical retropubic prostatectomy. Int J Impot Res 1996, 8(2):91–94

    CAS  PubMed  Google Scholar 

  2. Bahn DK, Silverman P, Lee F Sr, Badalament R, Bahn ED, Rewcastle JC: Focal prostate cryoablation: initial results show cancer control and potency preservation.J Endourol 2006 20(9):688–692

    Article  PubMed  Google Scholar 

Largest focal cryotherapy series published at the time of this report. Almost 90% of men remained sexually active, although half required oral medications.

  1. Poissonnier L, Chapelon JY, Rouviere O, Curiel L, Bouvier R, Martin X, Dubernard JM, Gelet A: Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 2007 51(2):381–387

    Article  CAS  PubMed  Google Scholar 

  2. Blana A, Rogenhofer S, Ganzer R, Wild PJ, Wieland WF, Walter B: Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer. World J Urol 2006 24(5):585–590

    Article  PubMed  Google Scholar 

  3. Madersbacher S, Pedevilla M, Vingers L, Susani M, Marberger M: Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res 1995 55(15):3346–3351

    CAS  PubMed  Google Scholar 

Early HIFU experience. Using technology now considered older, the authors found incomplete tumor destruction using focal HIFU.

  1. DiBiase SJ, Hosseinzadeh K, Gullapalli RP, Jacobs SC, Naslund MJ, Sklar GN, Alexander RB, Yu C: Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2002 52(2):429–438

    Article  PubMed  Google Scholar 

  2. Ellis RJ, Zhou H, Kim EY, Fu P, Kaminsky DA, Sodee B, Colussi V, Vance WZ, Spirnak JP, Kim C, Resnick MI: Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide. Brachytherapy 2007 6(1):16–25

    Article  PubMed  Google Scholar 

  3. Pawlicki T, Kim GY, Hsu A, Cotrutz C, Boyer AL, Xing L, King CR, Luxton G: Investigation of linac-based image-guided hypofractionated prostate radiotherapy. Med Dosim 2007 32(2):71–79

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urological Institute, The Cleveland Clinic Foundation, 9500 Euclid Ave St. A100, Cleveland, OH, 44195, USA

    J. Stephen Jones MD

Authors
  1. J. Stephen Jones MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Stephen Jones MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jones, J.S. Focal or Subtotal Therapy for Early Stage Prostate Cancer. Curr. Treat. Options in Oncol. 8, 165–172 (2007). https://doi.org/10.1007/s11864-007-0033-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-007-0033-1

Keywords

Search

Navigation